Formulation Development
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Trial With a microRNA-Targeted Technology
TransCode Therapeutics, Inc. recently announced it has dosed all patients in the first cohort of its Phase 1a dose-escalation clinical trial. The therapeutic candidate being…
Nanoscope Announces Plans to Submit BLA for Retinitis Pigmentosa Treatment
Nanoscope Therapeutics Inc. recently announced a productive FDA meeting for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP). Based on the regulatory…
Achieve Life Sciences Announces Completion of Enrollment in Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting
Achieve Life Sciences, Inc. recently announced an update on the ORCA-OL clinical trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen…
Palisade Bio Cleared to Commence Phase 1 Clinical Study for Ulcerative Colitis Treatment
Palisade Bio, Inc. recently announced it has received a No Objection Letter from Health Canada for its Phase 1 human clinical study for PALI-2108 for…
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
Can-Fite BioPharma Ltd. recently announced the its oncology drug candidate, Namodenoson, has been granted Orphan Drug Designation by the US FDA for the indication of…
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer
Panavance Therapeutics Inc. recently announced the presentation of interim data from its Phase 1 clinical study evaluating misetionamide (GP-2250) in combination with gemcitabine at the 2024…
BrainDos Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution in Preclinical Study
MetP Pharma AG, leveraging the proprietary nose-to-brain drug delivery technology BrainDos in internal and external product development and manufacturing programs, recently announced preclinical data showing…
Sonnet BioTherapeutics Enters Licensing Agreement With Alkem Laboratories
Sonnet BioTherapeutics Holdings, Inc. recently announced it has entered into a licensing agreement with Alkem Laboratories Limited for the research, development, manufacturing, marketing, and commercialization…
Syneos Health Appoints Costa Panagos as Chief Executive Officer
Syneos Health recently announced the appointment of Costa Panagos as CEO and a member of the company’s Board of Directors, effective immediately. Panagos succeeds….
HBC Immunology Completes In Vivo Drug Lead Studies for Prostrate Cancer Treatment
HBC Immunology (HBCI) recently announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral formulation…
Qinotto & Lilly Enter Research Collaboration & License Agreement
Qinotto, Inc. recently announced it has entered a research collaboration and license agreement with Eli Lilly and Company (Lilly) to discover next-generation antibody-based vehicles for…
Simtra BioPharma Solutions Expands Capabilities With $14M Investment in ADC Conjugation & Purification Clinical Suite
Simtra BioPharma Solutions recently announced a $14-million investment to expand its clinical-scale conjugation and purification capabilities for Antibody-Drug Conjugates (ADCs). Set to be operational by…
Mestag Therapeutics Announces License & Research Collaboration With MSD
Mestag Therapeutics recently announced it has entered into a license and collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, NJ) to identify…
Avalo Announces First Patient Dosed in Phase 2 Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Avalo Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS). AVTX-009 is…
Kindeva Drug Delivery Completes Registration Batch at State-of-the-Art Aseptic Injectable Fill-Finish Facility
Kindeva Drug Delivery recently announced two key milestones for its state-of-the-art Bridgeton, MO, facility. The site has successfully completed its first registration batch on its groninger…
MiNK Therapeutics & Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
MiNK Therapeutics and Autonomous Therapeutics, Inc. recently announced a research collaboration aimed at effectively targeting and treating metastatic tumors. This collaboration will leverage Autonomous’ precision…
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate
Traws Pharma, Inc. recently announced positive topline Phase 1 safety and pharmacokinetic results for its investigational one-dose influenza (flu) therapy, tivoxavir marboxil (tivoxavir). Tivoxavir was…
ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Trial of Lead cGAS Inhibitor Drug Candidate
ImmuneSensor Therapeutics recently announced the first dose level cohort of healthy volunteers has been dosed in a Phase 1 randomized, double-blinded, placebo-controlled clinical trial of…
GRIN Therapeutics Announces Initiation of Astroscape Clinical Trial of Radiprodil for Treatment of Tuberous Sclerosis Complex & Focal Cortical Dysplasia Type II
GRIN Therapeutics Inc. recently announced initiation of the Astroscape study, its global open-label clinical trial of radiprodil, an investigational, selective and potent negative allosteric modulator…
Veranova Expands Advisory Board With Distinguished Industry Leaders
Veranova recently announced the appointment of two distinguished industry leaders, Dr. Rajni Aneja and Dr. Bradley L. Pentelute, to its Advisory Board…..
